Filtered By:
Source: Heart Rhythm
Condition: Bleeding
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 42 results found since Jan 2013.
Stroke prevention in atrial fibrillation—An Asian stroke perspective
Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (~1%) than in Caucasians (~2%), Asia has a much higher overall disease burden because of its proportionally larger aged population. For example, on the basis of reported age-adjusted prevalence rates and projected population figures in China, there will be an estimated 5.2 million men and 3.1 million women with AF older than 60 years by year 2050. Stroke is a disabling complication of AF that is of increasing cause for concern in Asians patients. Implementing consensus expert recommendations for managing stroke risk in patients with AF can considerab...
Source: Heart Rhythm - March 18, 2013 Category: Cardiology Authors: Hung-Fat Tse, Yong- Jun Wang, Moheeb Ahmed Ai-Abdullah, Annette B. Pizarro-Borromeo, Chern-En Chiang, Rungroj Krittayaphong, Balbir Singh, Amit Vora, Chun-Xue Wang, Mohammad Zubaid, Andreas Clemens, Paul Lim, Dayi Hu Tags: Contemporary Review--Associate Editor: Sami Viskin Source Type: research
B-po03-148 risk stratification for ischemic stroke and major bleeding in patients without atrial fibrillation - validity of cha2ds2-vasc and has-bled score
Atrial fibrillation (AF) is the most common arrhythmia. Recent cardiac implantable electronic devices (CIEDs) have led to an improvement in the early detection of AF episodes. ESC guidelines for the management of AF recommend the use of CHA2DS2-VASc score as class I to predict the risk of ischemic stroke in patients with AF. However, the validity of the CHA2DS2-VASc and HAS-BLED scores to predict ischemic stroke and major bleeding events in patients without AF remains unclear.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Miyo Nakano, Yusuke Kondo, Masahiro Nakano, Takatsugu Kajiyama, Ryo Ito, Haruhiro Takahira, Mari Kitagawa, Masafumi Sugawara, Toshinori Chiba, Yoshio Kobayashi Source Type: research
Warfarin Use and the Risk of Mortality, Stroke, and Bleeding in Hemodialysis Patients with Atrial Fibrillation
The optimal management of stroke prophylaxis in hemodialysis patients with atrial fibrillation is controversial.
Source: Heart Rhythm - February 5, 2017 Category: Cardiology Authors: Brandon Kai, Yuliya Bogorad, Leigh-Ann N. Nguyen, Su-Jau Yang, Wansu Chen, Hillard T. Spencer, Albert Y.-J. Shen, Ming-Sum Lee Source Type: research
Benefits of non –vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention
The last decade has produced a large body of robust randomized controlled trial (RCT) data investigating the use of non –vitamin K antagonist oral anticoagulants (NOACs) in nonvalvular atrial fibrillation (AF).1–4 Compared with warfarin, dabigatran and apixaban have been found to reduce the combined outcome of stroke and systemic embolism. In addition, apixaban and edoxaban significantly reduce major bleeding. Fu rthermore, a pooled meta-analysis has demonstrated superior efficacy and overall safety of the NOACs.
Source: Heart Rhythm - January 15, 2017 Category: Cardiology Authors: Jay A. Montgomery, Gregory F. Michaud Tags: Editorial Commentary Source Type: research
B-po03-151 left atrial appendage occlusion as alternative approach for stroke prevention in hereditary hemorrhagic telangiectasia patients with atrial fibrillation
In this study, we evaluate the safety and efficacy of left atrial appendage occlusion (LAAO) for stroke prevention in HHT.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Mohammed Alghammass, Jad Aldanaf, Elizabeth Dranow, Kevin Whitehead Source Type: research
Ce-539-02 utilization of oral anticoagulation after bleeding events in stroke patients with atrial fibrillation
Oral anticoagulation (OAC) is recommended for stroke prophylaxis after diagnosis of atrial fibrillation (AF). However, the optimal strategy or timing for continuing OAC use after bleeding events in these patients has not been well established.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Paul Ziegler, shadi yaghi, Candace Gunnarsson, Michael Ryan, Sarah Rosemas, Matthew R. Reynolds Source Type: research
Po-01-140 atrial fibrillation and septic shock: a five-year retrospective observational study of anticoagulation usage, bleeding and stroke rates
Anticoagulation (AC) for atrial fibrillation (AF) is a cornerstone of management, and the benefit of mitigating stroke risk is accompanied by an increased risk of bleeding. The risk and benefit of AC in septic shock remains unclear as this disruptive hyperinflammatory state leads to multi-organ dysfunction, which can include coagulopathies.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Jonathan Na, Joanne Moon, Sahitya Allam, Maria Abraham, Kevin Chen, Ethan Kotloff, Yash Desai, Simin Hossain, Christopher Messner, Elnaz Esmati, Thomas Kutner, Gregory Norcross, James Childress, Paul Han, Ian Welch, Michael Sokolow, Libin Wang, Vincent Se Source Type: research
Left atrial appendage closure: A new technique for clinical practice
Conclusion: This review concludes that it is now appropriate to consider these techniques for patients with AF who are at high risk for stroke for whom effective conventional or novel anticoagulant therapy is not available or who present problems in managing drug treatment.
Source: Heart Rhythm - December 2, 2013 Category: Cardiology Authors: A John Camm, Antonio Colombo, Giorgio Corbucci, Luigi Padeletti Tags: Contemporary Review--Section Editor: Sami Viskin Source Type: research
Editorial Commentary: Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established and, in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1, 2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors as well as the incre...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Source Type: research
Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established, and in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1,2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation, possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors and to the increased...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Tags: Editorial Commentary Source Type: research
Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: A prospective single-center experience
Conclusions: Implantation of both LAA closure devices can be performed with high success rates in high-risk patients. Postprocedural 6 weeks antithrombotic therapy followed by aspirin therapy needs to be confirmed in a larger study.
Source: Heart Rhythm - August 26, 2013 Category: Cardiology Authors: KR Julian Chun, Stefano Bordignon, Verena Urban, Laura Perrotta, Daniela Dugo, Alexander Fürnkranz, Bernd Nowak, Boris Schmidt Tags: Clinical Source Type: research
Patients with atrial fibrillation and CHADS-VASc score 1: “To anticoagulate or not to anticoagulate? That is the question!”
There is uncertainty regarding the optimal therapy for preventing thrombo-embolic stroke in patients with atrial fibrillation and CHA2DS2-VASc score 1; in fact, no extensive data on this topic are available and the latest guidelines provide different recommendations. In this paper we examine current results on use of various anti-thrombotic agents in those patients, including the newer oral anticoagulant agents. Several factors must be considered and weighted in this setting and may influence the choice of the anti-thrombotic approach: the expected incidence of both thrombo-embolic stroke and bleeding complications as well...
Source: Heart Rhythm - July 15, 2015 Category: Cardiology Authors: Giuseppe Patti, Ilaria Cavallari Tags: CRV Source Type: research
EP News: Allied Professionals
In this paper, the authors (Poole et al J Am Coll Cardiol. 2020;75:3105-3118. PMID 32586583) provide expanded results of an important secondary endpoint of the CABANA (Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial, the recurrence of atrial fibrillation (AF). In the CABANA trial, 2204 patients with symptomatic AF and risk factors for stroke were randomized to catheter ablation or drug therapy with a primary endpoint was a composite of death, stroke, major bleeding or cardiac arrest during 5 years of follow-up.
Source: Heart Rhythm - July 7, 2020 Category: Cardiology Authors: Erica S. Zado Source Type: research
EP News: Clinical
Lakkireddy et al (Circulation 2021;144:1543, PMID 34459659) evaluated the safety and effectiveness of the Amulet left atrial appendage occluder (A) compared with the Watchman device (W). Patients with nonvalvular atrial fibrillation at an increased risk of stroke were randomly assigned (1:1) to A or W. The prim ary end points included safety (composite of procedure-related complications, death, or major bleeding at 12 months) and effectiveness (composite of ischemic stroke or systemic embolism at 18 months).
Source: Heart Rhythm - December 7, 2021 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research
Po-701-04 outcomes of left atrial appendage closure in patients with atrial fibrillation and end-stage renal disease on dialysis
Oral anticoagulation (OAC) therapy is the mainstay of treatment for stroke-risk reduction in patients with atrial fibrillation (AF). However, OAC use in patients with end-stage renal disease (ESRD) on dialysis is associated with a significantly increased risk of bleeding and an uncertain benefit in stroke reduction. In these patients, left atrial appendage closure (LAAC) could be alternative.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Jorge Romero, Juan C. Diaz, Sutopa Purkayastha, Jorge Marin, Julian M. Aristizabal, Daniel Rodriguez, Isabella Alviz, Mauricio Duque, Mohamed Gabr, Maria Gamero, Jose Matias, Marta Lorente-Ros, Luis Ernesto Cerna, Dhanunjaya R. Lakkireddy, Rishi Charate, Source Type: research
